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Abstract (247 words) 38!
Context: The human fetal adrenal (HFA) is an integral component of the feto-placental unit and important 39!
for the maintenance of pregnancy. Low kisspeptin levels during pregnancy are associated with miscarriage 40!
and kisspeptin / its receptor (Kiss1R) are expressed in the HFA. However, the role of kisspeptin in fetal 41!
adrenal function remains unknown.  42!
Objective: To determine the role of kisspeptin in the developing human fetal adrenal (HFA). 43!
Design: Experiments using H295R and primary HFA cells as in vitro models of the fetal adrenal. 44!
Association of plasma kisspeptin levels with HFA size in a longitudinal clinical study. 45!
Setting: Academic research center and tertiary fetal medicine unit. 46!
Participants: Thirty-three healthy pregnant women were recruited at their 12-week routine antenatal 47!
ultrasound scan. 48!
Main outcome measures: The spatio-temporal expression of Kiss1R in the HFA. The production of 49!
DHEAS from HFA cells following kisspeptin treatment, alone or in combination with ACTH or CRH. 50!
Fetal adrenal volume (FAV) and kisspeptin levels at 4 antenatal visits (~20, 28, 34 and 38 weeks gestation). 51!
Results: Kiss1R was present in the HFA from 8 weeks post conception to term and was shown for the first 52!
time within the inner fetal zone. Kisspeptin significantly increased DHEAS production in H295R and 53!
second trimester HFA cells. Serial measurements of kisspeptin confirmed a correlation with FAV growth in 54!
the second trimester, independent of sex or estimated fetal weight. 55!
Conclusions: Kisspeptin plays a key role in the regulation of the HFA and thus the feto-placental unit 56!
particularly in the second trimester of pregnancy. 57!
 58!
Precis (200 characters): Kisspeptin is a novel regulator of human fetal adrenocortical development and 59!
function. This suggests an important role for kisspeptin in the human feto-placental unit and maintenance 60!
of pregnancy. 61!
 62!
Abbreviations: Kiss1, kisspeptin gene; Kiss1R, kisspeptin receptor gene; Kiss1R, kisspeptin receptor, 63!
HFA, human fetal adrenal, FZ, fetal zone; DZ, definitive zone; TZ, transitional zone; DHEAS, 64!
dehydroepiandrosterone; DHEA, dehydroepiandrosterone sulfate; SULT2A1, Sulfotransferase Family 2A 65!




Kisspeptins are a family of peptide hormones encoded by the Kiss1 gene and are the endogenous ligands 69!
for the G-protein coupled receptor, Kiss1R in humans (1,2). Kiss1R is widely expressed in a number of 70!
human tissues including the hypothalamus and pituitary (1-3). In the latter, kisspeptin-Kiss1R signaling has 71!
a vital role in the secretion of GnRH at puberty (4,5). Kisspeptin and Kiss1R are robustly expressed in the 72!
syncytiotrophoblast cells of the placenta and may have an important role in the regulation of trophoblast 73!
invasion into the maternal uterine wall during placentation (1,6,7). In males and non-pregnant females, 74!
circulating kisspeptin levels are very low. Maternal circulating kisspeptin increases from around 8 weeks 75!
gestation by ~940 and >7000 fold in the second and third trimesters, respectively (8).  At ~5 days post-76!
partum, the levels fall to pre-pregnancy levels, implicating the placenta as the source of kisspeptin (8). 77!
Several studies suggest that low circulating maternal kisspeptin is associated with intra-uterine growth 78!
restriction and pre-eclampsia (9,10). Additionally, trophoblast expression of kisspeptin and its receptor in 79!
the first trimester is lower in women with recurrent miscarriage compared to normal pregnancies (11). 80!
Recently, a large prospective study demonstrated that plasma kisspeptin at the antenatal booking visit was 81!
reduced in women who later had miscarriages compared to those with normal pregnancies (12). Therefore 82!
there is compelling evidence to suggest that decreased kisspeptin may be a novel biomarker of placental 83!
dysfunction in pregnancy and may also identify asymptomatic pregnant women at greater risk of 84!
miscarriage. However, the mechanisms underlying these associations are unknown. 85!
 86!
The human fetal adrenal (HFA) cortex plays a critical role in the feto-placental unit and a pivotal role in the 87!
endocrine control of pregnancy and parturition (13-15). The developing HFA is composed of 3 zones, the 88!
centrally located fetal zone (FZ), the outer definitive zone (DZ) and the transitional zone (TZ) between the 89!
FZ and DZ (13,16). At ~8-10 weeks gestation (6-8 weeks post conception, wpc), there is rapid HFA growth 90!
due to enlargement of the FZ which accounts for most of the fetal adrenal mass by mid-gestation (16–20 91!
weeks gestation, 14-18wpc) (13,16,17). Except for transiently in the first trimester, FZ cells do not express 92!
the enzyme, 3βHSD, required for glucocorticoid and mineralocorticoid production. Therefore HFA 93!
steroidogenesis is characterized by early transient cortisol production, which is then suppressed until late 94!
gestation (16,17). The principal steroid output from the FZ in humans is DHEA, which is sulphated to 95!
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DHEAS by SULT2A1 before secretion (13). The placenta cannot produce estrogens de novo as it lacks the 96!
cytochrome P450 CYP17 enzyme (18). Therefore the functional role of the HFA is to produce steroid 97!
precursors, which are converted to estrogens by the placenta (19). Placental estrogens are critical for 98!
intrauterine homeostasis, fetal maturation and the activation of parturition (14,15,19). Consistent with this, 99!
a disproportionate enlargement of the HFA gland FZ may accurately predict impending pre-term birth 100!
(20,21). Soon after birth, the HFA undergoes rapid involution with rapid disappearance of the FZ and a 101!
decrease in androgen secretion (22,23). 102!
 103!
HFA development and function is complex and poorly understood. Although placental CRH and fetal 104!
pituitary ACTH play important roles, other locally produced or placenta-derived factors must also be 105!
involved (13). Interestingly, there is 50-fold higher expression of Kiss1R in the HFA compared to the adult 106!
adrenal and Kiss1R expression has been confirmed in the DZ and TZ of the HFA (24).  Additionally, 107!
kisspeptin stimulates aldosterone production in cultured human adrenocortical H295R cells (24). Therefore, 108!
the HFA may be an important target for the high levels of circulating kisspeptin in pregnancy.  109!
 110!
We investigated the hypothesis that kisspeptin is a novel regulator of human adrenocortical development 111!




Materials and Methods 115!
 116!
Ethical approval 117!
These studies were approved by the Brighton and Sussex Research Ethics Committee (REC reference: 118!
12/LO/1755). For the Finnish tissue samples, ethical approval was obtained from the Ethics Committee of 119!
the Pohjois-Savo Health Care District, Finland and a permit to study human autopsy tissues and resection 120!
material was obtained from the Finnish National Authority for Medicolegal Affairs.  121!
 122!
Adrenal tissues 123!
Tissue blocks from human fetuses following either therapeutic termination of pregnancy, miscarriage, 124!
stillbirth or intrauterine death were obtained at autopsies performed at Kuopio University Hospital, Finland. 125!
Cryosections of frozen HFA tissue were obtained from the MRC-Wellcome Trust Human Developmental 126!
Biology Resource (HDBR) (London and Newcastle). Maternal informed consent and approval from the 127!
local National Health Authority Ethics Committees was obtained. The age of the fetal samples was 128!
estimated as previously described (25)  and the embryos were staged using the Carnegie Staging 129!




Fresh HFA tissue, collected in ice-cold PBS (Sigma), was fixed in 4% paraformaldehyde, cryoprotected in 134!
30% sucrose and embedded in Optimal Cutting Temperature compound (OCT) (Fisher Scientific, 135!
Loughborough, UK). Sections (10µm) were cut using a cryostat (Leica GM 1510S). Haematoxylin and 136!
eosin (H and E) staining was performed using standard procedures. For immunofluorescence studies, 137!
sections were blocked for 30 minutes with 10% normal goat serum in PBS and then incubated with primary 138!
antibody (or control solution) overnight at room temperature followed by 2 hours incubation with donkey 139!
anti-rabbit secondary antibody (Jackson Immunoresearch). For negative controls, the primary antibody was 140!
omitted or pre-incubated with its peptide antigen (1µg/ml) at room temperature with agitation for 30 141!
minutes. Unbound antibody was removed by PBS-triton washes. Nuclei were stained with DAPI (4',6-142!
Diamidino-2-phenylindole dihydrochloride, 1µg/ml, Sigma Aldrich) and cover slips were secured with 143!
! 7!
fluorescent mounting media (Dako). Slides were visualized and images taken using the Zeiss LSM510 laser 144!
scanning confocal microscope and the ZEN 2011 Light edition software. For details of antibodies see 145!
Supplemental Table 1. 146!
 147!
Cell culture  148!
Ian Mason, University of Edinburgh donated the human adrenocortical carcinoma cell line (H295R; CRL-149!
2128). Primary HFA cells were derived from tissue samples obtained from the HDBR which were 150!
dissected and disaggregated by incubation at 37°C in serum-free DMEM/F12 Ham (1:1 ratio) media 151!
(DMEM/F12, Invitrogen) with 100 units/ml penicillin and 100µg/ml streptomycin (Pen/Strep, 152!
ThermoFisher Scientific) and 2mg/ml collagenase (Sigma Aldrich), for 90 minutes. Cells were then plated 153!
and grown as below. H295R and HFA cells were grown in DMEM/F12, with 2% Ultroser G (BioSepra), 154!
1% ITS (1mg/ml insulin, 0.55mg/ml transferrin and 0.5µg/ml sodium selenite, Sigma Aldrich) and 155!
Pen/Strep (27).  156!
 157!
cDNA synthesis and quantitative RT-PCR (qPCR) 158!
Total RNA was extracted from cultured H295R and HFA cells and human placental tissue using the 159!
RNeasy kit (QIAGEN). HFA RNA and adult adrenal RNA were obtained from the HDBR tissues and a 160!
Human Total RNA Master Panel II (Clontech), respectively and converted to cDNA using M-MLV 161!
Reverse Transcriptase according to manufacturer’s instructions (Promega). Quantitative RT-PCR was 162!
performed in triplicate (each sample) on a Stratagene Mx3000P thermocycler using KAPA SYBR fast 163!
quantitative PCR master mix with 200 nM forward and reverse primers (sequences available on request) 164!
Data were analyzed using MxPro software (Stratagene, Stockport, UK). The Ct value was quantified by 165!
interpolating the quantity from a standard curve made from a gel-purified amplicon. Data were normalized 166!
to GAPDH expression and presented as a proportional increase or decrease from the calibrator (placenta or 167!
adult adrenal normalized to a value of 1 for comparison). 168!
 169!
Cell treatments 170!
H295R and HFA cells were seeded into 6-well plates (Greiner Bio-One) and grown until 60-70% 171!
confluency then incubated in 1ml serum-free media overnight. 1ml fresh serum-free media alone 172!
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(untreated) or containing one of the following was added for 24h: 100nM Kisspeptin, 10nM CRH, 10nM 173!
ACTH or 10µM forskolin (Sigma Aldrich). CRH and ACTH directly stimulate DHEAS production in HFA 174!
cells (15,28). Forskolin treatment directs steroid production towards the androgen pathway in the H295R 175!
adrenocortical tumour cell line (27). DHEAS was measured in the cell media by enzyme linked 176!
immunosorbent assay (ELISA) (Demeditec Diagnostics, Kiel) and the assay quality was checked for some 177!
experiments by liquid chromatography–tandem mass spectrometry (LC-MS/MS). LC-MS/MS is the gold 178!
standard method for quantifying steroid production, however mass spectrometry results were unavailable 179!
for all the time points of interest. The kisspeptin concentration used was supraphysiological (100x maternal 180!
circulating concentrations). This was decided on the basis of previously published data (24) and dose 181!
response studies which showed a significant increase in DHEAS compared to untreated H295R cells with 182!
10nM (p<0.01) and 100nM (p<0.05). Only 100nM kisspeptin produced a significant increase in DHEAS 183!
compared to no treatment in 8-10wpc (p<0.05) and 15-20 HFA (p<0.0001) cells (Supplemental Figs. 1A, B 184!
and C, respectively). 185!
 186!
Protein assay 187!
The cell lysate protein concentrations were determined by Bradford assay (29). Absorbance of each well at 188!
595 nm (OD595) was determined using the Perkin Elmer Wallace Victor2 1420 Microplate reader. The 189!
protein content of each sample was determined as previously described (29).  190!
  191!
Immunoblotting 192!
Kiss1R expression was assessed by immunoblotting following treatment of cells with kisspeptin. Cells were 193!
lysed in 200 µl RIPA buffer (Sigma-Aldrich) containing protease inhibitor (complete, Mini, EDTA-free 194!
Protease Inhibitor Cocktail tablets, Roche). Samples were heated to 95°C for 5 minutes in Laemmli buffer 195!
(Sigma-Aldrich) and loaded on 4%–12% SDS-PAGE gels (Invitrogen). Size separated proteins were then 196!
transferred to a nitrocellulose membrane and the blots were immunolabeled overnight with the anti-Kiss1R 197!
antibody at 1:500 dilution or mouse monoclonal β-actin at 1:10,000 dilution (Sigma) as a loading control. 198!
Visualization of the proteins was performed using Alexa-fluor 680 and 800 secondary antibodies 199!




Cell media were collected from treated cells and DHEAS measurements were obtained using either the 203!
DHEAS ELISA Kit (Demeditec Diagnostics, Kiel) or LC-MS/MS utilizing an optimized protocol 204!
(Supplemental Methods and Supplemental Tables 2-4). Experiments were performed in triplicate and 205!
repeated at least three times. The DHEAS results were corrected to the protein content of the attached cells, 206!
quantified by Bradford assay.  207!
 208!
Clinical study design and recruitment 209!
A prospective observational study of patients with singleton, uncomplicated pregnancies was undertaken. 210!
Women attending their routine antenatal ultrasound scan (USS) at ~12 weeks gestation at the Royal 211!
London Hospital, London between February 2013 and April 2014 were recruited. Informed consent was 212!
obtained and translators were provided where necessary. Gestational age was established during the USS 213!
evaluation. Exclusion criteria included: multiple pregnancy, coexistent maternal medical conditions 214!
(hypertension, preeclampsia, diabetes, thyroid, adrenal or renal disease), congenital fetal abnormalities or 215!
chromosomal anomalies, maternal infection (including HIV), maternal alcohol abuse, heavy smoking (>10 216!
cigarettes daily prior to pregnancy; >5 cigarettes daily during pregnancy) and maternal exposure to 217!
psychotropic medications. Serial measurements of fetal adrenal size were performed at the time of the 218!
routine anomaly scan (~20 weeks gestation, visit 1) and at 3 other time points: ~28, 34 and 38 weeks 219!
gestation (visits 1-3, respectively) (Table 1). Maternal plasma samples for kisspeptin were taken at the 220!
same time points as the USS and subjects were followed up until the outcome of pregnancy was known. 221!
 222!
Subject details and pregnancy outcome 223!
Thirty-three pregnant women of mean age 26.8 ± 6.1 yrs were recruited. The median gravidity and parity of 224!
the women were 1 (range 1-4) and 0 (range 0-2), respectively. The patient demographics are detailed in 225!
Table 1 and Supplemental Table 5. Two subjects (21 and 23) moved area before completion of the study 226!
(after visits 2 and 3, respectively). Two babies were born prematurely at 26 and 33 weeks gestation (18 and 227!
30, respectively) with normal birth weights of 950 and 1340g (BW SDS 0.84 and -1.95), respectively. Two 228!
infants (6 and 22) born at 39.3 and 37.1 weeks gestation were small for gestational age, BW 2420 and 229!
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1720g (BW SDS -2.42 and -3.30), respectively. The remaining subjects had term deliveries, mean gestation 230!
39.96 ± 1.18 (range 37.14 - 42.14) and BW SDS -0.71 ± 0.87 (-3.30 - 0.57).  231!
 232!
Fetal adrenal volume calculation 233!
Fetal USS were performed by two fetal medicine doctors (RA, SM) independently using the Voluson 730 234!
and E8 systems (Voluson Expert; Milawaukee, WI). Two-dimensional measurements were taken in the 235!
transverse, coronal and sagittal planes to obtain the length, width and depth of the total adrenal gland and 236!
the fetal zone. Three dimensional ultrasonography was performed to obtain the adrenal gland volume 237!
which was calculated using VOCAL (Virtual Organ Computer-aided AnaLysis, 4D view; General 238!
Electrical Medical Systems) software (30). Adrenal volume data were missing in several patients who 239!
failed to attend USS appointments (Supplemental Table 5). 240!
 241!
Measurement of plasma kisspeptin  242!
Samples were stored at -20°C for between 6 and 18 months prior to kisspeptin measurements. Plasma 243!
kisspeptin immunoreactivity was measured at Imperial College, London using the established in-house 244!
assay (31,32).  245!
 246!
Data analysis and statistics  247!
In-vitro data were evaluated using a paired two-tailed Student’s t test or one-way ANOVA followed by a 248!
post-hoc Tukey comparisons test (GraphPad Prism 6, San Diego, CA). All experiments were performed in 249!
triplicate and represent 3 or 4 independent experiments; error bars depict the standard deviation of each 250!
individual experiment. Non-parametric continuous variables (FAV and kisspeptin levels) were analyzed by 251!
a Kruskal–Wallis test with Dunn-Bonferroni post hoc multiple comparison test correction. Continuous 252!
parametric variables (FAV in male and female fetuses) were compared using student t-test. R-values are 253!
Pearson's correlation coefficient (SPSS V.23 Armonk, New York, USA: IBM Corp.). P values <0.05 were 254!
statistically significant.  255!
 256!
Results   257!
 258!
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Expression of Kiss1R in the developing human fetal adrenal (HFA) cortex 259!
Immunohistochemical analysis demonstrated high expression of Kiss1R throughout the HFA cortex in all 260!
the gestational ages examined (8 wpc to term) (Fig. 1A, panels a-d). Co-localization studies using CD56 261!
and SULT2A1 as markers of the DZ/TZ and FZ, respectively, verify Kiss1R expression in all 3 zones of 262!
the HFA (Fig. 1B). Steroidogenic cells are identified by SF1 immunoreactivity throughout the HFA and 263!
there is co-localization of SF1 and Kiss1R (Supplemental Fig. 1D). Densely packed nuclei below the 264!
capsule and the larger cells in the center of the adrenal cortex have the appearance of DZ and FZ cells 265!
respectively, the TZ lies between these 2 zones (Fig. 1C). 266!
 267!
Quantitative assessment of Kiss1R expression in the developing HFA 268!
Kiss1R and SULT2A1 are highly expressed in the human placenta and adrenal gland respectively. 269!
Quantitative reverse-transcriptase PCR (qPCR) performed on 1st and 2nd trimester HFA cDNA (8-10wpc, 270!
11-14wpc, 15-20wpc) showed an increase in both Kiss1R (Fig. 1D) and SULT2A1 (Fig. 1E) mRNA 271!
expression with increasing gestational age. Kiss1R mRNA was significantly higher in 11-14wpc HFA (7.9-272!
fold, p<0.05) and 15-20 wpc HFA (22.3-fold, p<0.0001) than placenta (Fig. 1D). At 8-10wpc Kiss1R 273!
mRNA was 3.7-fold higher in HFA than in human placenta, although this was not significant (Fig. 1D). 274!
There was also a significant increase in Kiss1R expression from 8-10wpc to 15-20wpc (5.9 fold, p<0.0001) 275!
and 11-14wpc to 15-20wpc (2.8-fold, p<0.001). The 2-fold increase in Kiss1R expression between 8-10wpc 276!
and 11-14wpc was not significant.  277!
 278!
SULT2A1 mRNA was significantly higher in 11-14wpc (7.3-fold, p<0.05) and 15-20 wpc HFA (9.4-fold, 279!
p<0.01) than in human adult adrenal (Fig. 1E). At 15-20wpc SULT2A1 mRNA was 2.6-fold higher in HFA 280!
than at 8-10wpc (p<0.05). At 8-10wpc SULT2A1 mRNA was 3.6-fold higher in HFA than in adult adrenal, 281!
although this result was not significant (Fig. 1E). The 2.0- and 1.3-fold increase in SULT2A1 expression 282!
from 8-10wpc to 11-14wpc and 11-14wpc to 15-20wpc, respectively, were also not significant.  283!
 284!
The effect of kisspeptin treatment on Kiss1R mRNA and protein expression in H295R and HFA cells  285!
Treatment of H295R adrenocortical cells with kisspeptin resulted in a significant (60%) decrease in Kiss1R 286!
mRNA expression (Fig. 2A; p<0.05). A significant decrease (34%) in Kiss1R mRNA expression was also 287!
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observed in 15-20 wpc HFA cells (Fig. 2C; p<0.05) but not 8-10 wpc HFA cells (16% decrease, Fig. 2B) in 288!
response to kisspeptin treatment. Kisspeptin treatment also resulted in a significant decrease in Kiss1R 289!
protein levels in H295R adrenocortical cells (53.5% decrease from baseline; p<0.05) (Fig. 2D). Kiss1R 290!
protein expression was decreased in 8-10 week HFA cells (8.3% reduction; Fig. 2E) and 15-20 week HFA 291!
cells (8.9% reduction; Fig. 2F) in response to kisspeptin treatment, however these differences were not 292!
significant. 293!
 294!
The effect of kisspeptin and known adrenal regulators on DHEAS production (ELISA) in H295R and HFA 295!
cells  296!
Kisspeptin significantly increased DHEAS secretion from H295R, 8-10wpc and 15-20wpc HFA cells 3.7-297!
fold (p<0.05, Fig. 3A), 2.5-fold (p<0.05; Fig. 3B) and 4.0-fold (p<0.05; Fig 3C) compared to untreated 298!
cells, respectively. DHEAS production from 8-10wpc and 15-20wpc HFA cells following kisspeptin 299!
treatment was similar to that produced by ACTH (3.5-fold (p<0.01) and 4.1-fold (p<0.05) compared to 300!
untreated cells, respectively). Kisspeptin with forskolin increased DHEAS secretion 8.6-fold from H295R 301!
cells compared to untreated cells (p<0.0001), which was 2.3-fold (p<0.01) and 1.4 fold  (p<0.05) higher 302!
than kisspeptin or forskolin alone, respectively (Fig. 3A). Kisspeptin with ACTH also increased DHEAS 303!
production 4.5-fold (p<0.001; Fig. 3B) and 9.1-fold (p<0.0001, Fig. 3C) from 8-10wpc and 15-20wpc HFA 304!
cells compared to untreated cells, respectively. This was 1.7-fold (p<0.05; Fig. 3B) and 2.3-fold (p<0.01; 305!
Fig. 3C) higher than with kisspeptin alone in 8-10wpc HFA cells and 15-20wpc HFA cells, respectively 306!
and 2.2-fold (p<0.01; Fig. 3C) higher than with ACTH alone in 15-20wpc HFA cells.  307!
 308!
DHEAS production by H295R, 8-10wpc and 15-20wpc HFA cells following CRH treatment was similar to 309!
that produced by ACTH and kisspeptin treatment alone (4.0-fold (p<0.01), 4.0-fold (p<0.001) and 2.5-fold 310!
(p<0.05) compared to untreated cells, respectively) (Figs 3D-F). Compared to kisspeptin and CRH alone, 311!
treatment of H295R cells with a combination of kisspeptin and CRH resulted in a significant decrease (2.6-312!
fold; p<0.01 and 2.8-fold; p<0.01) in DHEAS production, respectively (Fig. 3D). The same pattern was 313!
observed in 8-10wpc HFA cells (3.1-fold (p<0.01) and 4.7-fold (p<0.001) decrease of DHEAS compared 314!
to kisspeptin and CRH treatment alone, respectively) (Fig 3E) and 15-20wpc HFA cells (3.5-fold (p<0.001) 315!
! 13!
and 2.2-fold (p<0.05) decrease of DHEAS compared to kisspeptin and CRH treatment alone, respectively) 316!
(Fig 3F).  317!
 318!
The effect of kisspeptin on DHEAS production (LC-MS/MS) in H295R and HFA cells  319!
DHEAS levels measured by LC-MS/MS increased 8.3-fold (H295R; p<0.05) and 93.2-fold (8-10wpc HFA 320!
cells; p<0.05) following kisspeptin treatment (Supplemental Figs. 1E & F and Supplemental Tables 4A & 321!
B). These DHEAS increases are 2.2 and 34.5 fold higher compared to the ELISA assay, respectively. The 322!
lower calculated fold change observed by the ELISA analysis compared to the LC-MS/MS assay in 8-323!
10wpc HFA cells can be attributed to the higher baseline values. This is likely to be due to interference in 324!
the ELISA assay at baseline from other steroid sulfates generated by the HFA tissue.  325!
 326!
Fetal adrenal volume and kisspeptin levels in uncomplicated singleton pregnancies 327!
Fetal adrenal volumes (FAV) increase steadily during pregnancy (Fig. 4A & Supplemental Table 5). 328!
Median FAVs were 0.19 cm3 (IQR 0.08-0.48; n=31), 0.52 cm3 (0.26-1.53; n=32), 1.52 cm3 (0.94-2.40; 329!
n=28) and 2.16 cm3 (1.17-7.87; n=23) at antenatal visits 1-4, respectively. The range of FAVs increase as 330!
gestation advances but there are significant increases in FAV between visits 1 and 2 (p<0.01), visits 1 and 3 331!
(p<0.001), visits 1 and 4 (p<0.001) and visits 2 and 4 (p<0.01). Median kisspeptin levels were 2822 pmol/L 332!
(IQR 1913-0.48; n=33), 3953 pmol/L (2823-5615; n=31), 4545 pmol/L (3182-6182; n=30) and 3711 333!
pmol/L (2546-4937; n=26) at antenatal visits 1-4, respectively (Fig. 4B). There is considerable overlap of 334!
kisspeptin levels as gestation advances but significant increases are noted between visits 1 and 2 (p<0.05), 335!
visits 1 and 3 (p<0.001), visits 1 and 4 (p<0.001) and visits 2 and 4 (p<0.01) (Fig. 4B). 336!
 337!
Relationship between fetal adrenal volume and plasma kisspeptin in singleton pregnancies 338!
To corroborate the in-vitro data, we assessed the association of the maternal kisspeptin levels with the 339!
subsequent FAV increment at the four different time points. The mean increase in FAV between antenatal 340!
visits 1 and 2 correlated with the kisspeptin level at visit 1 (r=0.41, p=0.026) (Fig. 4C), suggesting that the 341!
kisspeptin levels between 19-20 weeks gestation (17-18 wpc) may influence FAV increase between 19-28 342!
weeks gestation (17-26 wpc). There was no significant difference in the mean rise of FAV between the 1st 343!
and 2nd antenatal visits in male 0.83 ± 0.94 (n=18) and female 1.28 ± 1.38 (n=12) infants, respectively 344!
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(p=0.30, 95% CI: -0.42 to 1.31). There was no significant correlation between FAV and estimated fetal 345!
weight (efw) between the 1st and 2nd antenatal visits (r -0.166; p=0.36). Therefore, the significant 346!
correlations between maternal kisspeptin and FAV were independent of fetal sex and efw, suggesting that 347!
kisspeptin may be important for FA development in mid-pregnancy. There was no significant correlation 348!
between the maternal kisspeptin levels and the subsequent FAV increment at the other antenatal time 349!




Circulating kisspeptin levels increase dramatically during pregnancy (8) and may have an important role in 354!
placentation by regulating placental invasion into the maternal uterine wall (1,3,6). Circulating kisspeptin 355!
levels are reduced in women with intrauterine growth retardation and preeclampsia (9,33) and low maternal 356!
levels in early pregnancy have been associated with greater miscarriage risk (12). Therefore, kisspeptin 357!
may be a novel endocrine marker of functional placental tissue and low placental kisspeptin may be 358!
associated with serious obstetric complications. The role of kisspeptin in pregnancy and the mechanisms 359!
underlying these associations are unclear. 360!
 361!
Kisspeptin and its receptor, Kiss1R, are expressed in the central nervous system, pancreas, adipose tissue, 362!
testes and spleen (2,3). One other group has assessed the expression and localization of Kiss1R in the 363!
human fetal adrenal gland (HFA) (24).  This study showed robust expression of Kiss1R mRNA in HFA 364!
tissue and Kiss1R protein expression in the definitive and the transitional zones (DZ and TZ) of 14-36 365!
weeks gestation HFA tissues by immunohistochemistry. For the first time, we confirmed Kiss1R protein 366!
expression in the HFA cortex from 8 weeks post conception (wpc; 10 weeks gestation) to term by 367!
immunofluorescence. Interestingly, it was identified throughout the adrenal cortex, with expression in the 368!
inner FZ as well as the outer DZ and TZ. The reason for this discrepancy is unclear but may be accounted 369!
for by the different methodology and antibody used. Additionally, our immunofluorescence and in-vitro 370!
data concord as presumably, kisspeptin stimulates DHEAS production from FZ cells. Consistent with this, 371!
SULT2A1 (DHEA sulphotransferase) is localized to the FZ and converts DHEA to DHEAS. This suggests 372!
that the FZ may represent an important target for kisspeptin during pregnancy.  373!
! 15!
 374!
Quantitative evaluation shows that Kiss1R mRNA expression increases significantly in mid-gestation (11-375!
20 wpc); therefore this may be a critical time point for the action of kisspeptin on the FZ. The production of 376!
DHEAS begins at ~8-10 weeks gestation (6-8wpc) but increases considerably during the second and third 377!
trimesters (13). The increase in Kiss1R expression in mid-gestation (11-20 wpc) is paralleled by an increase 378!
in SULT2A1 mRNA expression. Taken together, these data suggest that the FZ is an important target for 379!
kisspeptin, particularly in the second trimester.  380!
 381!
Kiss1R is a G-protein coupled receptor (GPCR). Kisspeptin-KISS1R signaling is best characterized in 382!
GnRH neurons and in these cells, KISS1R undergoes both kisspeptin-triggered and kisspeptin-independent 383!
signaling, internalization and recycling (34). This ensures a dynamic population of functional cell-surface 384!
receptors and tight regulation of the biochemical response. In HFA cells, kisspeptin treatment resulted in a 385!
significant decrease in Kiss1R mRNA expression in adrenocortical tumor (H295R) and second trimester 386!
HFA cells. This was paralleled by a significant decrease in Kiss1R protein levels in H295R cells. This data 387!
is novel and we hypothesise that high circulating kisspeptin levels may down-regulate Kiss1R expression in 388!
the HFA to regulate signaling and therefore ensure tight control of steroidogenesis throughout pregnancy. 389!
This process of desensitization is a recognized phenomenon of many other GPCRs (35) as well as 390!
kisspeptin (36). 391!
 392!
ACTH secreted from the fetal pituitary is a crucial regulator of FA growth partly mediated by peptide 393!
growth factors in an autocrine or paracrine fashion (13,24). Placental CRH and estrogens may also play 394!
important roles in the development of the FA. However, the rapid growth and steroid output of the FZ 395!
during the second trimester are not paralleled by an increase in ACTH and in humans, CRH levels peak 396!
near parturition. (13). This suggests that other pregnancy-specific factors regulate FZ growth and function, 397!
particularly in the second trimester.  398!
 399!
It is established that ACTH and CRH directly promote DHEAS production from FA cells (15,37) but the 400!
regulation of androgen production from FZ cells is not fully understood. One previous study has shown that 401!
kisspeptin can increase aldosterone production from H295R cells (24). Its role in the production of other 402!
! 16!
steroidogenic hormones by the HFA has not previously been examined. Our ELISA data confirm that 403!
kisspeptin can significantly increase DHEAS production from H295R and 8-10 / 15-20wpc (10-22 weeks 404!
gestation) HFA cells. Analysis by LC-MS/MS showed a similar response for H295R. For 8-10 wpc HFA 405!
cells, the baseline values were much higher by ELISA, so that the calculated fold change was much higher. 406!
This is likely to be due to interference in the ELISA assay from other steroid sulfates generated by this 407!
tissue. Paradoxically, DHEAS values post kisspeptin are lower by ELISA than by LC-MS/MS, which 408!
supports the concept that kisspeptin specifically stimulates DHEAS production. The kisspeptin effect was 409!
comparable to stimulation with ACTH or CRH alone. Furthermore, kisspeptin in combination with ACTH 410!
appears to augment this effect. In contrast, CRH in combination with kisspeptin significantly decreased 411!
DHEAS production.  Thus kisspeptin may work in concert with CRH and ACTH to regulate HFA function 412!
and therefore the balance of estrogens during pregnancy. The placenta is the primary source of estrogen 413!
and the concentration of estrogen increases with progressing gestational age. The timing of these 414!
interactions may be critical as ACTH levels remain fairly steady throughout pregnancy and circulating 415!
kisspeptin levels rise steadily between the first and third trimesters. Consequently as pregnancy progresses, 416!
kisspeptin may work in tandem with ACTH to enhance DHEAS, the production of estrogens and the 417!
maintenance of pregnancy. In support of this hypothesis, low levels of kisspeptin, particularly in early 418!
pregnancy, are associated with greater miscarriage risk (12).  419!
 420!
CRH is postulated to play critical roles in fetal maturation and the onset of parturition. Consequently, the 421!
levels of CRH increase as pregnancy progresses and peak from 35 weeks gestation corresponding with a 422!
fall in the level of cortisol binding protein. Abnormal activation of the fetal HPA and enlargement of the 423!
FAV has been associated with impending preterm birth (20,21). It is feasible that kisspeptin modulates the 424!
effects of CRH in mid gestation however, its role in late pregnancy when CRH is critical, warrants further 425!
investigation. 426!
 427!
3-D ultrasonography (3DUS) is an established and accurate method of assessing fetal organ volumes. More 428!
recently it has been reported as a reliable technique to measure HFA volume, with good intra- and inter-429!
observer repeatability (30,38). One cross-sectional study reports correlations between FAV and estimated 430!
fetal weight (efw) and FAV and gestational age (GA) (39). Interestingly, our data suggest that FAV was 431!
! 17!
independent of both GA and efw. This discrepancy may be explained by the fact that our data was 432!
longitudinal and is therefore is more likely to show true correlations. Chang et al observed larger FAVs 433!
than those obtained in the current study (39) and two other groups report slightly lower FAVs at 434!
comparable GAs (20,38). These differences may be attributed to different methodologies and inclusion 435!
criteria employed. Additionally, all three studies report cross sectional rather than longitudinal data. 436!
Importantly, the FAV measurements in the current study are in agreement with data obtained from a 437!
detailed postmortem study (40).  438!
 439!
Circulating kisspeptin concentrations increase dramatically during pregnancy and its levels reflect the 440!
amount of viable placental tissue (8). Consequently a decline in the levels may be associated with increased 441!
miscarriage and preeclampsia (10,12). This was also demonstrated in twin pregnacies where the death of 442!
one twin was associated with lower kisspeptin levels (12).  Serial measurements of plasma kisspeptin in 443!
pregnant women have not previously been undertaken but cross-sectional data suggest that the levels 444!
increase as pregnancy progresses (8). We report a significant increase in circulating kisspeptin in pregnant 445!
females between 20 and 28 weeks gestation which correlates with the second trimster rise in FAV. This 446!
increase in FAV is independent of sex and efw. It also coincides with the in vitro data, which shows a 447!
significant increase in Kiss1R mRNA expression in second trimester (13-22 weeks) HFA cells and DHEAS 448!
production from mid-trimester (10-22 gestation) HFA cells following kisspeptin treatment. 449!
 450!
In summary, kisspeptin-Kiss1R signaling may be a key regulator of HFA development and steroidogenesis 451!
and therefore an integral component of the feto-placental unit. As well as being critical in the regulation of 452!
placentation in early pregnancy, it may have a key physiological role in intrauterine homeostasis and the 453!
maintenance of pregnancy, particularly in the second trimester. Therefore, our data suggests a novel 454!
functional role for kisspeptin in utero. 455!
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Figure and Table Legends 576!
 577!
Figure. 1. Expression of Kiss1R in the developing human fetal adrenal (HFA) cortex. A. 578!
Immunofluorescence studies of the HFA from 8wpc to term (panel a. 8wpc, b.11wpc, c. 33wpc, d & e. 579!
38wpc). Localization of Kiss1R (red) in the definitive zone, DZ, transitional zone, TZ and throughout the 580!
fetal zone, FZ (panels a-d). No immunoreactivity is detected in the negative control with antigen (Kiss1R) 581!
pre-incubation (Kiss1R-con, panel e), demonstrating specificity of the Kiss1R antibody. The adrenal cortex 582!
is surrounded by an outer mesenchymal capsule (dashed line). Scale bar: 100µm. B. Co-localization studies 583!
of HFA at 12wpc (panels a-c). CD56 (green) is expressed in the outer DZ/TZ (panels a & b) and SULT2A1 584!
(red) in the inner FZ (panel b). Kiss1R (red) is seen throughout the cortex (FZ and DZ) (panel a). No 585!
immunoreactivity detected in the negative controls where the primary antibodies (CD56 and SULT2A1) 586!
were omitted (panel c, CD56-con, SULT2A1-con). The capsule is shown (dashed line). Scale bar:  100µm. 587!
C. H&E staining of HFA 33wpc. A thin capsule (c) surrounds the outer definitive zone (DZ). The DZ of 588!
the cortex is the most superficial layer with closely packed, darker stained cells. The deeper layer with the 589!
more eosinophilic appearance is the fetal zone (FZ). The transitional zone (TZ) lies between the outer DZ 590!
and inner FZ. Scale bar: 1mm (panel a), 100µm (panel b). D. Kiss1R qPCR was performed on cDNA 591!
obtained from 3 HFA samples from each stage of development (8-10wpc, 11-14wpc, 15-20wpc). Placental 592!
cDNA was used as a positive control. Data points represent the mean +/- SD from 4 independent 593!
experiments performed in triplicate. E. SULT2A1 qPCR was performed on cDNA obtained from 3 HFA 594!
samples from each stage of development (8-10wpc, 11-14wpc, 15-20wpc). Adult adrenal cDNA was used 595!
as a positive control. Data points represent the mean +/- SD from 3 independent experiments performed in 596!
triplicate. D&E. Data are normalized to GAPDH expression and presented as a proportional increase or 597!
decrease from the calibrator (placenta and adult adrenal, normalized to a value of 1 for comparison). 598!
*p<0.05; **p<0.01 ***p<0.001; ****p<0.0001. 599!
 600!
Figure. 2 The effect of kisspeptin treatment on Kiss1R mRNA and protein expression in H295R and 601!
primary fetal adrenocortical cells.  602!
Treatment with 100nM kisspeptin for 24 hrs significantly reduced Kiss1R mRNA expression in H295R 603!
cells (A). This was also evident in HFA 15-20wpc (C) but not 8-10wpc (B). Data are normalized to 604!
! 23!
GAPDH expression and presented as a proportional increase or decrease from the control (unstimulated 605!
cells, normalized to a value of 100 for comparison). Data points represent the mean +/- SD from 3 606!
independent experiments performed in triplicate. D-F. Densitrometric analysis of Western blots showed a 607!
significant reduction in Kiss1R protein following treatment of H295R cells with 100nM kisspeptin for 24 608!
hours (D) but not 8-10wpc HFA cells (E) or 15-20wpc (F). Data points represent the mean +/- SD from 3 609!
independent experiments performed in triplicate. β-actin was used as a loading control. *p<0.05.  610!
 611!
Figure. 3 The effect of kisspeptin and known adrenal regulators on DHEAS production (ELISA) in 612!
H295R and primary fetal adrenocortical cells.  613!
  614!
A-F. DHEAS production (ELISA) by H295R and HFA cells following kisspeptin and CRH treatments. 615!
H295R cells were incubated for 24 hours with 100nM kisspeptin and 10µM forskolin individually or 616!
together (A). 8-10wpc HFA cells (B) and 15-20 wpc HFA cells (C) were incubated for 24 hours with 617!
100nM kisspeptin and 10nM ACTH individually or together. D-F DHEAS production (ELISA) by H295R 618!
and HFA cells following kisspeptin and CRH treatments. H295R cells (D), 8-10wpc HFA cells (E) and 619!
HFA cells 15-20wpc (F) were incubated for 24 hours with 100nM kisspeptin or 10nM CRH individually or 620!
together. Data points are mean +/- SD from 3 independent experiments run in triplicate and expressed as 621!
the fold over basal level (normalized to a value of 1). (-), no treatment; (+), treatment added. *p<0.05; 622!
**p<0.01; ***p<0.001; ****p<0.0001. 623!
 624!
Figure 4. Human fetal adrenal gland volumes and kisspeptin levels in the maternal circulation 625!
during pregnancy 626!
A and B Box and whisker plots (A) of fetal adrenal gland volumes (FAV; cm3) and (B) Maternal serum 627!
kisspeptin levels at the 4 antenatal visits (visit 1, 19-20 weeks; visit 2, 26-28 weeks; visit 3, 34-35 weeks; 628!
visit 4, 37-40 weeks). Box plots show the median, upper and lower quartiles and interquartile range (IQR). 629!
Open circles, outliers; star, extreme outliers. *p<0.05; **p<0.01; ***p<0.001. C and D Scatter Plots 630!
showing (C) The correlation between the kisspeptin level at the 1st visit and the increase in FAV between 631!
the 1st and 2nd antenatal visits. r, pearson coefficient. 632!
 633!
! 24!
Table 1. Details of the patients, the timing of the antenatal assessments and pregnancy outcome 634!
 635!
Patient characteristic Mean ±  SD Range N 
Age (years)  26.8 ± 6.1 17.0 - 37.0 33 
BMI  25.4 ± 5.3 18.8 - 41.1 33 
Gestational age (weeks)  
   Visit 1 
   Visit 2 
   Visit 3 
   Visit 4 
 
20.35 ± 0.68 
28.07 ± 0.75 
34.42 ± 0.75 
38.09 ± 0.62 
 
19.29 - 22.57 
26.29 - 29.86 
33.00 - 36.14 






Gestation at delivery (weeks)  39.33 ± 2.83 26.86 - 42.14 31 
Birth weight (grams) 3006 ± 650 950 - 3680 31 
Birth weight SDS -0.698 ± 0.913 -3.30 - 0.840 31 
 636!
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Supplemental Figure 1 
Supplemental Table 1. Details of antibodies used for immunofluorescence studies 
 






1° SF1 Mouse monoclonal Invitrogen (434200) 1 in 200 
2° AF488-Green Goat anti-mouse Invitrogen (A11029) 1 in 1000 
1° Kiss1R Rabbit polyclonal Alomone (AKR-001) 1 in 100 
2° CY3-Red Donkey anti-rabbit Jackson Immunoresearch 
(711-165-152) 
1 in 1000 
1° SULT2A1 Rabbit polyclonal Abcam (38416) 1 in 200 
2° CY3-Red Donkey anti-rabbit Jackson Immunoresearch 
(711-165-152) 
1 in 1000 
1° CD56-conjugated  
AF488-Green 
Mouse monoclonal Invitrogen MHCD5620 1 in 1000 
 


















DHEAS measurements using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
500µl of precipitation reagent (a cocktail of internal standards in acetonitrile, including 16,16 d2 
DHA sulfate) was added to the samples, calibrators and internal quality controls (500µl). The 
quality controls were created in-house from a standard solution of DHA sulfate diluted in charcoal-
stripped serum.  Samples were vortexed (30 seconds) and centrifuged (13 000rpm) for 5 minutes. 
The supernatant was transferred into glass tubes. Bicarbonate solution (200µl, 8% aq, v/v) and 1ml 
of ethyl acetate was added and the tubes were vortexed (30 seconds) and centrifuged (13 000 rpm) 
for 5 minutes. The organic layer was transferred into a glass tube and evaporated to dryness under 
nitrogen gas and reconstituted in 125µl of freshly prepared reconstitution solution (Mobile phase A: 
Mobile phase B, 65:35 (v/v)). 100µl was injected onto the liquid chromatography (LC) system. 
Using the TSQ Vantage (ThermoFisher) in MS/MS positive APCI mode, m/z transitions 271.1 to 
105 & 91 were monitored. DHEA was also quantified in the same runs and remained near or below 
detection limits, indicating that there was no significant desulfation during sample processing. 
Mass spectrometry parameters are listed in Supplemental Table 2 and method validation data is 
listed in Supplemental Table 3.  Comparison of ELISA and LC-MS/MS DHEAS concentrations are 
given in Supplemental Table 4. 
 
Liquid chromatography conditions 
Eluents: Mobile Phase A:  Water with 0.1 % formic acid  
  Mobile Phase B:   Methanol with 0.1 % formic acid   
Flow rate:    0.4ml/min 
Column:              Accucore RP-MS Column (100 x 2.1mm. 2.6 µm) 













Discharge current (mA) 5.0 
Sheath gas 20 
Aux gas 5 
Collision gas pressure (mTorr) 1.5 
Q1 (FWHM): 0.40 
Q3 (FWHM): 0.70 





























Supplemental Table 3. DHEAS assay validation data 
A. Precision and accuracy 
Concentration 
nmol/L (n=6) 
102 204 1697 8148 
Intra-assay 
Mean 99.8 187.3 1840 8080 
Accuracy % 97.9 92 108 99 
CV% 5.3 3.0 3.8 1.3 
Inter-assay 
Mean 102.3 201.7 1789.7 
 
7700.8 
Accuracy % 100.3 98.9 105.5 94.5 
CV% 8.1 3.7 5.6 4.7 
 
Lower limit of quantification is 35 nmol/L. No carry over or carry under was detected. No Ion 
suppression/enhancement of DHEAS-d2 signal was noted 
 
B. Reagent stability 
Concentration 
nmol/L (n=3) 
204 1697 5729 
Post extraction 1 week at 4°C 
Mean 201.4 1646 5720 
Accuracy % 96.7 97.0 99.8 
Post extraction 1 week at room temperature 
Mean 202.4 1570 5539.3 
Accuracy % 99.2 92.5 96.7 
3 freeze-thaw cycles 
Mean 203.2 1633 5581 
Accuracy % 99.6 96.2 97.4 
Supplemental Table 4. ELISA vs LC-MS/MS data 
 




















































































Un, unstimulated cells; KP, cells treated with 100nM kisspeptin. * Fold change calculated relative 
to untreated samples which are normalized to 1.0. 
 
